Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US10085937 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9480644 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9707226 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 November, 2015
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
23
United States
3
Japan
3
European Union
2
Israel
2
Singapore
2
Russia
2
Mexico
2
Canada
2
China
1
United Kingdom
1
Germany
1
Hong Kong
1
IB
1
Australia
1
Spain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic